Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome

Jung-Yien Chien, Po-Ren Hsueh, Wern-Cherng Cheng, Chong-Jen Yu, Pan-Chyr Yang, Jung-Yien Chien, Po-Ren Hsueh, Wern-Cherng Cheng, Chong-Jen Yu, Pan-Chyr Yang

Abstract

Objective and background: Pathological changes in severe acute respiratory syndrome (SARS) suggest that SARS sequelae are associated with dysregulation of cytokine and chemokine production. To improve understanding of the immuno-pathological processes involved in lung injury associated with SARS, the temporal changes in cytokine/chemokine profiles in the sera of SARS patients were compared with those of patients with community-acquired pneumonia (CAP), according to the degree of lung involvement.

Methods: Serum levels of 11 cytokines and chemokines, in 14 patients with SARS and 24 patients with CAP, were serially checked using a bead-based multiassay system. Sera from 12 healthy subjects were used as normal controls.

Results: The serum levels of interferon-gamma-inducible protein-10 (IP-10), IL-2 and IL-6 were significantly elevated during SARS infection. In patients with CAP, but not in those with SARS, the levels of interferon-gamma, IL-10, IL-8 and monokine induced by interferon-gamma (MIG) were significantly elevated compared with the levels in healthy controls. Among the chemokines/cytokines, IL-6 levels correlated most strongly with radiographic scores (r=0.62). The elevation of IP-10 and IL-2 antedated the development of chest involvement and reached peak levels earlier than the radiographic scores. In contrast, the dynamic changes in IL-6, C-reactive protein and neutrophils occurred synchronously with the changes in radiographic scores. The mean ratio of IL-6 to IL-10 in SARS patients (4.84; range 0.41-21) was significantly higher than that in CAP patients (2.95; range 0.02-10.57) (P=0.04).

Conclusions: The early induction of IP-10 and IL-2, as well as the subsequent over-production of IL-6 and lack of IL-10 production, probably contribute to the main immuno-pathological processes involved in lung injury in SARS. These changes in cytokine/chemokine profile are remarkably different from those observed in CAP patients.

Figures

Figure 1
Figure 1
Cytokine/chemokine profiles in the blood of patients with severe acute respiratory syndrome (SARS) and community‐acquired pneumonia (CAP). (a–k) Levels of the cytokines interferon (IFN)‐, tumour necrosis factor (TNF)‐, IL‐6, IL‐5, IL‐4, IL‐2, IL‐10; and the chemokines monocyte chemoattractant protein (MCP)‐1, monokine induced by IFN‐γ (MIG), IFN‐γ‐inducible protein‐10 (IP‐10) and IL‐8 in the blood of patients with SARS or CAP at different stages: A, admission; C, convalescent stage; N, normal control; P, progressive stage; W, worst stage. *P < 0.05 compared with normal control group. **P < 0.05 SARS (▪) versus CAP () groups.
Figure 2
Figure 2
Association between levels of interferon‐γ‐inducible protein‐10 (IP‐10) (a), IL‐2 (b), IL‐6 (c), CRP (d), neutrophil count (e), and lymphocyte count (f), and radiographic score during severe acute respiratory syndrome (SARS) infection. Data from all stages of SARS infection was pooled. Linear regression and correlation were analysed; r = correlation coefficient. CRP, C‐reactive protein.
Figure 3
Figure 3
Changes in the levels of interferon‐γ‐inducible protein‐10 (IP‐10) (a), IL‐2 (b), IL‐6 (c) and lymphocyte count (d) in the blood of patients with severe acute respiratory syndrome at different stages: A, admission; C, convalescent stage; N, normal control; P, progressive stage; W, worst stage. () Radiographic score; (—▴—) IP‐10; (—◆—) IL‐2; (—•—) IL‐6; (—▵—) lymphocyte.

References

    1. Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003; 348: 1953–66.
    1. Wong KT, Antonio GE, Hui DS et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003; 228: 401–6.
    1. Ooi CG, Khong PL, Ho JC et al. Severe acute respiratory syndrome: radiographic evaluation and clinical outcome measures. Radiology 2003; 229: 500–6.
    1. Tang NL, Chan PK, Wong CK et al. Early enhanced expression of interferon‐inducible protein‐10 (CXCL‐10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin. Chem. 2005; 51: 2333–40.
    1. Huang KJ, Su IJ, Theron M et al. An interferon‐gamma‐related cytokine storm in SARS patients. J. Med. Virol. 2005; 75: 185–94.
    1. World Health Organization . Severe acute respiratory syndrome (SARS). Wkly. Epidemiol. Rec. 2003; 78: 81–3.
    1. Hsueh PR, Hsiao CH, Yeh SH et al. Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome. Taiwan. Emerg. Infect. Dis 2003; 9: 1163–7.
    1. Wong CK, Lam CW. Clinical applications of cytokine assays. Adv. Clin. Chem. 2003; 37: 1–46.
    1. Tarnok A, Hambsch J, Chen R, Varro R. Cytometric bead array to measure six cytokines in twenty‐five microliters of serum. Clin. Chem. 2003; 49: 1000–2.
    1. Ooi CG, Khong PL, Lam B et al. Severe acute respiratory syndrome: relationship between radiologic and clinical parameters. Radiology 2003; 229: 492–9.
    1. Mogensen TH, Paludan SR. Molecular pathways in virus‐induced cytokine production. Microbiol. Mol. Biol. Rev. 2001; 65: 131–50.
    1. Ishiguro N, Takada A, Yoshioka M et al. Induction of interferon‐inducible protein‐10 and monokine induced by interferon‐gamma from human endothelial cells infected with influenza A virus. Arch. Virol. 2004; 149: 17–34.
    1. Miller AL, Bowlin TL, Lukacs NW. Respiratory syncytial virus‐induced chemokine production: linking viral replication to chemokine production in vitro and in vivo . J. Infect. Dis. 2004; 189: 1419–30.
    1. Mule JJ, Shu S, Rosenberg SA. The anti‐tumor efficacy of lymphokine‐activated killer cells and recombinant interleukin 2 in vivo . J. Immunol. 1985; 135: 646–52.
    1. Nicholls JM, Poon LL, Lee KC et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361: 1773–8.
    1. Jiang Y, Xu J, Zhou C et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am. J. Respir. Crit. Care Med. 2005; 171: 850–7.
    1. Franks TJ, Chong PY, Chui P et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum. Pathol. 2003; 34: 743–8.
    1. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine‐mediated inflammation in acute lung injury. Cytokine Growth Factor Rev. 2003; 14: 523–35.
    1. Zhang Y, Li J, Zhan Y et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect. Immun. 2004; 72: 4410–15.
    1. Wong CK, Lam CW, Wu AK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004; 136: 95–103.
    1. Jones BM, Ma ES, Peiris JS et al. Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids. Clin. Exp. Immunol. 2004; 135: 467–73.
    1. Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community‐acquired pneumonia and their association with disease severity. Eur. Respir. J. 2002; 20: 990–5.
    1. Monton C, Torres A, El‐Ebiary M et al. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit. Care Med. 1999; 27: 1745–53.
    1. Leemans JC, Vervoordeldonk MJ, Florquin S, Van Kessel KP, Van Der Poll T. Differential role of interleukin‐6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus . Am. J. Respir. Crit. Care Med. 2002; 165: 1445–50.
    1. Skoner DP, Gentile DA, Patel A, Doyle WJ. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. J. Infect. Dis. 1999; 180: 10–14.
    1. Rube CE, Rodemann HP, Rube C. [The relevance of cytokines in the radiation‐induced lung reaction. Experimental basis and clinical significance]. (German). Strahlenther Onkol. 2004; 180: 541–9.
    1. Bhandari V. Developmental differences in the role of interleukins in hyperoxic lung injury in animal models. Front. Biosci. 2002; 7: d1624–33.
    1. Thomson AW, Lotze MT. The Cytokine Handbook, 4th edn Academic Press, San Diego, CA, USA, 2003.
    1. Law HK, Cheung CY, Ng HY et al. Chemokine up‐regulation in SARS‐coronavirus‐infected, monocyte‐derived human dendritic cells. Blood 2005; 106: 2366–74.
    1. Peiris JS, Chu CM, Cheng VC et al. Clinical progression and viral load in a community outbreak of coronavirus‐associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767–72.
    1. Kaiser L, Briones MS, Hayden FG. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J. Clin. Virol. 1999; 14: 191–7.
    1. Arend WP, Joslin FG, Thompson RC, Hannum CH. An IL‐1 inhibitor from human monocytes. Production and characterization of biologic properties. J. Immunol. 1989; 143: 1851–8.
    1. Miyaoka K, Iwase M, Suzuki R et al. Clinical evaluation of circulating interleukin‐6 and interleukin‐10 levels after surgery‐induced inflammation. J. Surg. Res. 2005; 125: 144–50.
    1. Ng PC, Lam CW, Li AM et al. Inflammatory cytokine profile in children with severe acute respiratory syndrome. Pediatrics 2004; 113: e7–14.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren